<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831440</url>
  </required_header>
  <id_info>
    <org_study_id>ZKX10022</org_study_id>
    <nct_id>NCT01831440</nct_id>
  </id_info>
  <brief_title>Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging</brief_title>
  <official_title>The Influence of Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging：A Comparative Longitudinal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the level of residual symptoms and psychosocial
      factors affecting recovery of psychosocial functions in MDD patients who reach remission, and
      investigate the recovery process of psychosocial functions.

      The investigators suppose that even the patient is well-treated by drug,there are still many
      residual symptoms,and they also exist different degree of damage in the structure and
      functions of brain. CBT could help them obtain better recovery,especially in psychosocial
      functions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:At present, clinical remission of depression is defined as a final HAMD score of
      less than 7. However, in clinical practice, the psychosocial functions of patients who reach
      remission are far from complete recovery. The recovery of psychosocial functions lags behind
      the disappearance of symptoms.so,we aim to determine the level of residual symptoms and
      psychosocial factors affecting recovery of psychosocial functions in MDD patients who reach
      remission, and investigate the recovery process of psychosocial functions.

      Method:200 MDD patients who met the inclusion criteria were randomly divided into CBT group
      and control group.All of subjects would complete the psychological assessment at
      0,1st,2nd,6th and 12th months for CBT group and 0,2nd,12th months for control group.ALL
      participants would undergo magnetic resonance imaging at 0,2nd,12th months.The scanning
      sequence is 3D,resting-state,task-state and diffusion tensor imaging（DTI）.During the magnetic
      resonance imaging（MRI） scans, subjects performed the facial and gender recognition tasks with
      three different facial stimuli(positive/neutral/negative).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression (HAMD）</measure>
    <time_frame>one year</time_frame>
    <description>The 24-item version of the Hamilton Rating Scale for Depression (HAMD; Hamilton, 1960) will be used for measuring severity of depressive symptoms.remission of depression is defined as a final HAMD score of less than 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging</measure>
    <time_frame>one year</time_frame>
    <description>Scanning sequency：3D、resting-state、task-state、Diffusion Tensor Imaging（DTI） Task:explicit and implicit emotional processes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Beck Depression Inventory (BDI)</measure>
    <time_frame>one year</time_frame>
    <description>The Beck Depression Inventory (BDI), created by Dr. Aaron T. Beck, is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic Quality of Life Inventory-74</measure>
    <time_frame>one year</time_frame>
    <description>Generic Quality of Life Inventory-74(GQOLI-74)created by Dr.Yang Desen and Dr. Li Lingjiang in 1998. It will be used for measuring the quality of life,efficacy and side effect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>medicine combined CBT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Besides clinical routine antidepressant treatment,participants receive CBT weekly for 8 weeks and monthly until the end of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medicine (SSRI antidepressants)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>clinical routine antidepressant treatment——Selective serotonin reuptake inhibitors（SSRIs）.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>medicine combined CBT</intervention_name>
    <description>medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.</description>
    <arm_group_label>medicine combined CBT</arm_group_label>
    <other_name>antidepressant combined cognitive-behavioral therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medicine</intervention_name>
    <description>Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.</description>
    <arm_group_label>medicine (SSRI antidepressants)</arm_group_label>
    <other_name>SSRI antidepressants</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of major depressive disorder (MDD)

          -  Hamilton Rating Scale for Depression(HAMD) less than 7

        Exclusion Criteria:

          -  Bipolar disorder

          -  Substance dependence

          -  Neurological disorder or other mental disorder

          -  Severe body disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhang Ning</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Brain Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ma Hui</last_name>
    <phone>025-82296357</phone>
    <email>mahui_njmu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanjing Brain Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ma Hui</last_name>
      <phone>025-82296357</phone>
      <email>mahui_njmu@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhang Ning</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.cbtchina.com.cn/</url>
    <description>Click here for more information about Chinese Cognitive-Behavioral Therapy(CCBT)</description>
  </link>
  <reference>
    <citation>Mattisson C, Bogren M, Horstmann V, Munk-Jörgensen P, Nettelbladt P. The long-term course of depressive disorders in the Lundby Study. Psychol Med. 2007 Jun;37(6):883-91. Epub 2007 Feb 19.</citation>
    <PMID>17306047</PMID>
  </reference>
  <reference>
    <citation>Kuehner C. An evaluation of the 'Coping with Depression Course' for relapse prevention with unipolar depressed patients. Psychother Psychosom. 2005;74(4):254-9.</citation>
    <PMID>15947516</PMID>
  </reference>
  <reference>
    <citation>Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, Moore R, Jenaway A, Cornwall PL, Hayhurst H, Abbott R, Pope M. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry. 1999 Sep;56(9):829-35.</citation>
    <PMID>12884889</PMID>
  </reference>
  <reference>
    <citation>Watkins E, Scott J, Wingrove J, Rimes K, Bathurst N, Steiner H, Kennell-Webb S, Moulds M, Malliaris Y. Rumination-focused cognitive behaviour therapy for residual depression: a case series. Behav Res Ther. 2007 Sep;45(9):2144-54. Epub 2007 Mar 26.</citation>
    <PMID>17367751</PMID>
  </reference>
  <reference>
    <citation>Petersen TJ. Enhancing the efficacy of antidepressants with psychotherapy. J Psychopharmacol. 2006 May;20(3 Suppl):19-28. Review.</citation>
    <PMID>16644768</PMID>
  </reference>
  <reference>
    <citation>Vitiello B. Combined cognitive-behavioural therapy and pharmacotherapy for adolescent depression: Does it improve outcomes compared with monotherapy? CNS Drugs. 2009;23(4):271-80.</citation>
    <PMID>19374457</PMID>
  </reference>
  <reference>
    <citation>Scott J, Teasdale JD, Paykel ES, Johnson AL, Abbott R, Hayhurst H, Moore R, Garland A. Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. Br J Psychiatry. 2000 Nov;177:440-6.</citation>
    <PMID>11059998</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>April 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <last_update_submitted>April 12, 2013</last_update_submitted>
  <last_update_submitted_qc>April 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Ning Zhang</investigator_full_name>
    <investigator_title>Vice-President of Nanjing Brain Hospital</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>remission</keyword>
  <keyword>Pharmacotherapy</keyword>
  <keyword>psychotherapy</keyword>
  <keyword>neuroimaging</keyword>
  <keyword>psychology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

